{"id":"NCT00127530","sponsor":"Acorda Therapeutics","briefTitle":"Study of Oral Fampridine-SR in Multiple Sclerosis","officialTitle":"Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-05","primaryCompletion":"2006-06","completion":"2006-09","firstPosted":"2005-08-08","resultsPosted":"2011-05-06","lastUpdate":"2018-09-11"},"enrollment":300,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Sclerosis"],"interventions":[{"type":"DRUG","name":"Fampridine-SR","otherNames":["Sustained release 4-aminopyridine, 4-AP"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo- sugar pill","type":"PLACEBO_COMPARATOR"},{"label":"Fampridine-SR","type":"EXPERIMENTAL"}],"summary":"To assess the safety and efficacy of 10 milligram (mg) twice a day (b.i.d.) Fampridine-SR in patients diagnosed with multiple sclerosis (MS), in a double-blind, placebo-controlled, parallel group study.","primaryOutcome":{"measure":"Timed Walk Responders (Patients Who Showed Consistent Improvement on the Timed-25 Foot Walk)","timeFrame":"Days 14, 42, 70 and 98 of treatment, corresponding to the four on-drug visits during double-blind treatment period.","effectByArm":[{"arm":"Placebo- Sugar Pill","deltaMin":6,"sd":null},{"arm":"Fampridine-SR","deltaMin":78,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":34,"countries":["United States","Canada"]},"refs":{"pmids":["19249634"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":72},"commonTop":["fall","Urinary Tract Infection","dizziness","insomnia","Upper Respiratory Tract infection"]}}